Development of a HA1-specific enzyme-linked immunosorbent assay against pandemic influenza virus A H1N1
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Doo Hee | - |
dc.contributor.author | Kim, Min Jung | - |
dc.contributor.author | Cha, Hye-Ran | - |
dc.contributor.author | Park, Eun Sun | - |
dc.contributor.author | Kim, Ah Reum | - |
dc.contributor.author | Park, Jeon Han | - |
dc.contributor.author | Park, Hyung-Cheon | - |
dc.contributor.author | Song, Daesub | - |
dc.contributor.author | Lee, Jae Myun | - |
dc.date.accessioned | 2021-09-01T21:52:53Z | - |
dc.date.available | 2021-09-01T21:52:53Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-01 | - |
dc.identifier.issn | 2287-3651 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/68432 | - |
dc.description.abstract | Purpose: Enzyme-linked immunosorbent assay (ELISA) has been used in the diverse field to evaluate influenza virus infection; for the surveillance, diagnosis, efficacy evaluation, and development of the vaccine. The aim of this study was to establish an ELISA for detecting HA strain-specific antibodies using recombinant pandemic A H1N1 (pH1N1) HA1 (rHA1) protein. Materials and Methods: rHA1 was produced in baculovirus system. The clinical performance of the developed ELISA was validated using human serum samples, by comparison with standard methods for detecting a neutralizing antibody; hemagglutination inhibition (HI) assay and microneutralization test (MNT). The ability of the ELISA system to evaluate the efficacy test of an influenza vaccine was explored by measuring antibody levels in the serum of vaccinated mice. Results: Our ELISA could detect anti-rHA1 antibody in influenza-infected patients and vaccinated subjects. Compared to HI assay and MNT as reference methods, our method showed good performance in detection of anti-rHA1 antibody. Detection of the anti-rHA1 antibody in vaccinated mice and its correlation with titers in HI assay was also proved in a mice model. Conclusion: An ELISA system using rHA1 of pH1N1 influenza virus was developed, and showed good clinical performance in diagnosis of influenza virus infection and evaluation of the vaccination efficacy in both human and animal models. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN VACCINE SOC | - |
dc.title | Development of a HA1-specific enzyme-linked immunosorbent assay against pandemic influenza virus A H1N1 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Daesub | - |
dc.identifier.doi | 10.7774/cevr.2019.8.1.70 | - |
dc.identifier.scopusid | 2-s2.0-85062651301 | - |
dc.identifier.wosid | 000458219500008 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL VACCINE RESEARCH, v.8, no.1, pp.70 - 76 | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL VACCINE RESEARCH | - |
dc.citation.title | CLINICAL AND EXPERIMENTAL VACCINE RESEARCH | - |
dc.citation.volume | 8 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 70 | - |
dc.citation.endPage | 76 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002435930 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordAuthor | Influenza A virus | - |
dc.subject.keywordAuthor | H1N1 subtype | - |
dc.subject.keywordAuthor | Infection | - |
dc.subject.keywordAuthor | Enzyme-linked immunosorbent assay | - |
dc.subject.keywordAuthor | Vaccination | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.